Search Medical Condition
Please enter condition
Please choose location from dropdown

Sankt Petersburg, Russian Federation Clinical Trials

A listing of Sankt Petersburg, Russian Federation clinical trials actively recruiting patients volunteers.

RESULTS

Found (286) clinical trials

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced Platinum-Ineligible Bladder Cancer (BAYOU)

This is a Phase II, randomized, double-blind, placebo controlled, multi-center, comparative global study to determine the efficacy and safety of durvalumab + olaparib combination therapy versus durvalumab + placebo (durvalumab monotherapy) as first-line treatment in patients ineligible for platinum-based chemotherapy with unresectable Stage IV urothelial cancer (UC).

Phase

4.13 miles

Learn More »

Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections

Purpose of the study: To assess additional data of efficacy and safety of the drug Anaferon in the treatment of acute respiratory viral infections

Phase

4.13 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

The study consists of four phases: 4-week Screening Phase 24-week placebo-controlled phase Subjects will receive either 0.45 mg QD, 0.3 mg QD, 0.15 mg QD or placebo for the first 24 weeks of treatment. 28-week active treatment phase At Week 24, all subjects on placebo will be re-randomized to active ...

Phase

4.45 miles

Learn More »

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

This is a multicentre, randomized, double-blind, placebo controlled, parallel group study designed to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without OCS. Approximately 1060 subjects will be ...

Phase

4.59 miles

Learn More »

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Patients

The total duration of the study (per patient) is approximately 36 weeks, including 4 weeks screening, 12 weeks treatment, and 20 weeks post-treatment.

Phase

4.59 miles

Learn More »

Proof-of-Concept Study to Assess the Efficacy Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Study participation for each patient will be up to a total of 46 weeks to 76 weeks including up to 10 days to 4 weeks of screening, 24 to 52 week treatment period on investigational medical product (IMP), and 20 weeks of post IMP treatment period.

Phase

4.59 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

The purpose of this study is to evaluate the efficacy and safety of mirikizumab in participants with moderate to severe plaque psoriasis.

Phase

4.64 miles

Learn More »

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

Phase

4.64 miles

Learn More »

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

This is a 24 week, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the effects of saxagliptin and sitagliptin on cardiac dimensions and function in patients with type 2 diabetes (T2DM) mellitus and heart failure (HF).

Phase

4.67 miles

Learn More »

Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S Topical Spray and ANTI-ANGIN FORMULA Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx Accompanied by a Sore Throat

The purpose of this study is to evaluate no less therapeutic efficacy and safety of the Angal S, topical spray [Menthol], 0,5 mg + 2 mg (Sandoz dd, Slovenia) compared to ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC "Valeant", Russia) in treatment of patients with uncomplicated ...

Phase

4.67 miles

Learn More »